RxDoctor Payments Data

Hussain Al-Darsani, MD

Gastroenterology · Chino, CANPI 1669429775

Payments from drug & device makers

$4,917in general payments, 2019–2025

Across 275 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$628
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$611
  • Bristol Myers Squibb$520
  • Ferring Pharmaceuticals Inc.$455
  • Gilead$408
  • Phathom Pharmaceuticals, Inc.$281
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,86399%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,917 in reported general payments places this provider in the 60th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$84,672
Medicare patients
300
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide212$129,005
VemlidyTenofovir Alafenamide32$47,875
XifaxanRifaximin11$32,593
CreonLipase/Protease/Amylase59$31,058
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates398$23,054
MovantikNaloxegol Oxalate29$11,263
ClenpiqSod Picosulf/Mag Ox/Citric Ac59$10,181
Mesalamine19$6,467
Entecavir15$5,771
Sucralfate119$5,343
Budesonide EcBudesonide11$5,190
Omeprazole313$4,426
Ursodiol49$3,777
Cholestyramine LightCholestyramine54$3,765
Lansoprazole159$3,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$628$160,063271 claims
GileadVemlidy$408$47,87532 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$611$32,59311 claims
Redhill Biopharma Inc.Movantik$166$11,26329 claims
Ferring Pharmaceuticals Inc.Clenpiq$455$10,18159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Chino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →